We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy and safety of low dose ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis.
- Authors
Qing Chen; Yuanyuan Zhang; Zhen Wang; Shuai Wang; Hao Zhang; Yiwen Wang; Chi Lu; Haochen Xuan; Chaofan Wang; Dongye Li; Tongda Xu; Chen, Qing; Zhang, Yuanyuan; Wang, Zhen; Wang, Shuai; Zhang, Hao; Wang, Yiwen; Lu, Chi; Xuan, Haochen; Wang, Chaofan
- Abstract
Our aim was to examine clinical trials, provide guidance to practitioners and estimate the efficacy and safety of two agents by comparing low dose ticagrelor with standard dose clopidogrel in patients with acute coronary syndrome. We systematically looked through Pubmed, Embase, the Cochrane Library, Wanfang data and CNKI for trials comparing low dose ticagrelor with standard dose clopidogrel for the treatment of patients with ACS since the database was created. The primary endpoint for efficacy was the rate of major adverse cardiac events (MACEs). The primary endpoint for safety was the rate of major bleeding events. We also evaluated platelet function between low dose ticagrelor and standard dose clopidogrel in ACS patients. From 6744 articles, 16 studies including 1629 patients met the inclusion criteria. In contrast with standard dose clopidogrel, low dose ticagrelor significantly reduced MACEs (OR 0.39, 95% CI 0.26, 0.58) and the difference was statistically significant (p<0.01). No difference was noted for major bleeding events (OR 1.16, 95% CI 0.43, 3.08) between the two agents (p=0.77). In addition, low dose ticagrelor showed lower platelet aggregation rate than clopidogrel (standardised mean difference (SMD) -0.68, 95% CI -0.83 to 0.53) (p<0.01). Platelet reaction units for low dose ticagrelor were much lower than those for standard dose clopidogrel (SMD -2.46, 95% CI -2.85 to -2.07) (p<0.01). In comparison with standard dose clopidogrel, low dose ticagrelor significantly lowered the incidence of MACEs, improved left ventricular ejection fraction, decreased left ventricular end diastolic dimension and did not expand the risk of major bleeding events or minor or minimal bleeding events in ACS patients with a considerable safety and efficacy profile. In addition, low dose ticagrelor was associated with dramatically lower platelet aggregation compared with standard dose clopidogrel.
- Subjects
ACUTE coronary syndrome; TICAGRELOR; PLATELET aggregation inhibitors; CORONARY disease; EAST Asians; META-analysis; SYSTEMATIC reviews; TREATMENT effectiveness; DOSE-effect relationship in pharmacology; MEDICAL prescriptions; DRUG side effects
- Publication
Postgraduate Medical Journal, 2020, Vol 96, Issue 1141, p693
- ISSN
0032-5473
- Publication type
journal article
- DOI
10.1136/postgradmedj-2019-137180